Highlights

  • Mach7 Technologies (ASX:M7T) reported FY26 Revenue of A$27.9 million, in line with company guidance.
  • Recurring revenue reached A$23.4 million, representing 84% of total revenue.
  • Operating expenses declined 16% to A$26.7 million following cost restructuring initiatives.
  • The company recorded positive Operating Cash Flow for three consecutive quarters in FY26.
  • Mach7 Technologies traded at AUD 0.28, up 1.82% during the morning session on 28 August 2026.

Mach7 Technologies Limited (ASX:M7T) has reported its FY26 results, outlining progress across its healthcare imaging software business, including increased Recurring Revenue contribution, cost base restructuring and expansion of its product offering. The company said the second half of FY26 showed improvement across key metrics as it continued executing its strategic priorities.

During the morning session on 28 August 2026, Mach7 Technologies (ASX:M7T) was trading at AUD 0.28, up 1.82%. The stock remains down 15.15% over the past year, based on the provided market information.

Business Reset

Mach7 Technologies provides enterprise imaging software solutions designed for healthcare organisations managing diagnostic imaging data across complex environments. Its platform includes solutions such as the Vendor Neutral Archive (VNA), the eUnity Enterprise Diagnostic Viewer and Flamingo modules supporting workflow, interoperability and data management.

The company described FY26 as a period of Business reset, with focus placed on restructuring the cost base, protecting recurring revenue and strengthening its Leadership team.

Mach7 CEO and Managing Director Teri Thomas said the second half demonstrated progress across strategic priorities, with initiatives including product expansion, cost restructuring and a renewed customer engagement model contributing to measurable outcomes such as new customer wins, growth from the installed base and the first Flamingo deployment.

Financial Results

Mach7 reported total revenue of A$27.9 million for FY26, down 17% compared with the prior corresponding period. The company attributed the decline mainly to fewer one-off Capital software licence deals, while noting the result was in line with FY26 revenue guidance.

Recurring revenue was A$23.4 million, accounting for 84% of total revenue compared with 75% in FY25. Recurring revenue coverage of operating expenditure improved to 88%, compared with 80% in the previous year.

The company reported operating expenses of A$26.7 million, down 16% on the prior corresponding period due to cost restructuring and ongoing cost discipline.

Adjusted EBITDA was -A$0.9 million for FY26, compared with -A$0.3 million in FY25, while improving from -A$2.3 million in H1 FY26. NPATA was -A$2.9 million, compared with A$0.4 million in FY25, and NPAT was -A$8.9 million compared with -A$6.2 million previously.

Mach7 ended FY26 with A$19.9 million in cash and no debt, compared with A$23.1 million in cash at 30 June 2025.

Revenue Mix

The company said FY26 revenue performance reflected a shift towards recurring revenue streams, with growth from new and existing customers partially offset by the non-renewal of Trinity Health and the cessation of the Veteran’s Health Administration contract during H1 FY26.

Mach7 also highlighted the first Flamingo module implementation, which was completed within a short timeframe and contributed to customer expansion activity.

The company’s ARR Run Rate reached A$23.5 million at 30 June 2026, representing a 7.6% increase on a constant currency basis compared with 30 June 2025.

Growth Priorities

Mach7 said its focus for FY27 remains on execution, including improving customer outcomes, securing new customers, expanding revenue from its installed base and demonstrating operating leverage.

The company also plans to continue selective Investment in innovation and growth opportunities where returns are clear.

Mach7’s platform continues to support healthcare organisations worldwide, including integrated delivery networks, national health systems and specialist imaging providers. The company is also expanding its capabilities through cloud ecosystem alignment with platforms such as Amazon Web Services and Oracle Cloud Infrastructure.

Investor Takeaway

Mach7 Technologies’ FY26 update highlights a transition period focused on recurring revenue growth, cost management and operational restructuring. Investors may continue watching customer adoption, expansion of the installed base, further product deployments and progress towards improved Operating Leverage as the company enters FY27.